Cancer therapy directed by comprehensive genomic profiling: a single center study Ovarian Cancer and Us OVARIAN CANCER and US Ovarian Cancer and Us

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Sunday, May 22, 2016

Cancer therapy directed by comprehensive genomic profiling: a single center study



full text (pdf)
 May 18, 2016



We report the findings of a prospective, single-center study conducted in patients with diverse refractory cancers who underwent comprehensive genomic profiling (CGP; next-generation sequencing, 236 genes). Of
the 500 patients enrolled, 188 (37.6%) received either matched (N=122/188, 65%) or unmatched therapy (N=66/188, 35%). The most common reasons that patients were not evaluable for treatment included insufficient tissue, death, o rhospice transfer. The median number of molecular alterations per patient was five (range, 1-14); median number of prior therapies, four. The most common diagnoses were ovarian cancer (18%), breast cancer (16%),
sarcoma (13%), and renal cancer (7%). Of the 339 successfully-profiled
patients, 317 (93.5%) had at least one potentially actionable alteration. …….Collectively, this study offers a clinical proof of concept for the  utility of CGP in assigning therapy to patients with refractory malignancies, especially in those patients with multiple genomic aberrations for whom combination therapies could be implemented.

 

0 comments :

Post a Comment

Your comments?